FDA Denies Intarcia’s Request to Alter AdComm Procedures for Diabetes Treatment

The FDA will not let Intarcia choose reviewers for the upcoming Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) meeting to consider the company’s troubled diabetes drug-device product, nor will the agency grant other requests Intarcia made last month.
Source: Drug Industry Daily